1. |
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treat-ment of acute venous thromboembolism. N Engl J Med, 2013, 369 (9): 799-808.
|
2. |
Kirley K, Qato DM, Kornfield R, et al. National trends in oral anti-coagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes, 2012, 5(5): 615-621.
|
3. |
Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitaliza-tions for adverse drug events in older Americans. N Engl J Med, 2011, 365(21): 2002-2012.
|
4. |
Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic comp-lications in African-American and European-American patients on warfarin. Clin Pharmacol Ther, 2008, 83(2): 312-321.
|
5. |
张亚同, 梁欣, 董凡, 等. 中国人群CYP4F2基因多态性对华法林抗凝作用的影响. 临床药物治疗杂志, 2014, 12(1): 41-45.
|
6. |
Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogene-tics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 2010, 115(18): 3827-3834.
|
7. |
闻武, 黄烽, 阳丽梅, 等. CYP2C93, VKORC1-1639G>A和CYP4F2 rs2108622基因多态性对华法林剂量的影响. 中国胸心血管外科临床杂志, 2013, 20(4): 375-380.
|
8. |
Bress A, Patel SR, Perera MA, et al. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics, 2012, 13(16): 1925-1935.
|
9. |
Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associa-ted with warfarin dose in African-American individuals: a genome-wide association study. Lancet, 2013, 382(9894): 790-796.
|
10. |
Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet, 2010, 19(23): 4735-4744.
|
11. |
NⅡnuma Y, Saito T, Takahashi M, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J, 2014, 14(2): 107-114.
|
12. |
鲁晓春, 李世英. 中国人VKORC1基因多态性对华法林维持剂量影响的Meta分析. 心肺血管病杂志, 2012, 31(3): 259-263.
|
13. |
Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood, 2008, 111(8): 4106-4112.
|
14. |
McDonald MG, Rieder MJ, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol, 2009, 75(6): 1337-1346.
|
15. |
Jorgensen AL, FitzGerald RJ, Oyee J, et al. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. Plos One, 2012, 7(8): e44064.
|
16. |
Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood, 2009, 113(4): 784-792.
|
17. |
Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood, 2008, 112(4): 1022-1027.
|
18. |
Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet, 2009, 5(3): e1000433.
|
19. |
Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol, 2013, 168(4): 4234-4243.
|
20. |
Finkelman BS, Gage BF, Johnson JA, et al. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol, 2011, 57(5): 612-618.
|
21. |
王永, 许金国, 万镇, 等. 综合CYP2C9、VKORC1基因型和INR值建立华法林个体化剂量公式. 临床合理用药杂志, 2014, 7(1): 112-113.
|
22. |
Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-Ⅱ). Circulation, 2012, 125(16): 1997-2005.
|
23. |
Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med, 2013, 369(24): 2283-2293.
|
24. |
Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 2013, 369(24): 2294-2303.
|
25. |
Avery PJ, Jorgensen A, Hamberg AK, et al. A proposal for an indivi-dualized pharmacogenetics-based warfarin initiation dos regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther, 2011, 90(5): 701-706.
|
26. |
Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther, 2008, 84(3): 326-331.
|
27. |
Verhoef TI, Redekop WK, Daly AK, et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol, 2014, 77(4): 626-641.
|
28. |
Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther, 2010, 87(4): 459-464.
|
29. |
Holbrook A, Schulman S, Witt DM, et al. Evidence-based manage-ment of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e152S-e184S.
|
30. |
Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogene-tics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther, 2011, 90(4): 625-629.
|
31. |
Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med, 2014, 174(8): 1330-1338.
|
32. |
Liao Z, Feng S, Ling P, et al. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. J Thromb Thrombolysis, 2015, 39(2): 228-234.
|
33. |
Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Ameri-cans. Pharmacogenomics J, 2014, 14(3): 223-228.
|